Is psychological, social, and economic stress associated with coronavirus disease 2019 (COVID-19) associated with the incidence of stress cardiomyopathy?
This cohort study included 1914 patients with acute coronary syndrome to compare patients presenting during the COVID-19 pandemic with patients presenting across 4 timelines prior to the pandemic and found a significantly increased incidence of 7.8% of stress cardiomyopathy during the COVID-19 pandemic, compared with prepandemic incidences that ranged from 1.5% to 1.8%.
These findings suggest that psychological, social, and economic stress related to the COVID-19 pandemic was associated with an increased incidence of stress cardiomyopathy.
The coronavirus disease 2019 (COVID-19) pandemic has resulted in severe psychological, social, and economic stress in people’s lives. It is not known whether the stress of the pandemic is associated with an increase in the incidence of stress cardiomyopathy.
To determine the incidence and outcomes of stress cardiomyopathy during the COVID-19 pandemic compared with before the pandemic.
Design, Setting, and Participants
This retrospective cohort study at cardiac catheterization laboratories with primary percutaneous coronary intervention capability at 2 hospitals in the Cleveland Clinic health system in Northeast Ohio examined the incidence of stress cardiomyopathy (also known as Takotsubo syndrome) in patients presenting with acute coronary syndrome who underwent coronary arteriography. Patients presenting during the COVID-19 pandemic, between March 1 and April 30, 2020, were compared with 4 control groups of patients with acute coronary syndrome presenting prior to the pandemic across 4 distinct timelines: March to April 2018, January to February 2019, March to April 2019, and January to February 2020. Data were analyzed in May 2020.
Patients were divided into 5 groups based on the date of their clinical presentation in relation to the COVID-19 pandemic.
Main Outcomes and Measures
Incidence of stress cardiomyopathy.
Among 1914 patient presenting with acute coronary syndrome, 1656 patients (median [interquartile range] age, 67 [59-74]; 1094 [66.1%] men) presented during the pre–COVID-19 period (390 patients in March-April 2018, 309 patients in January-February 2019, 679 patients in March-April 2019, and 278 patients in January-February 2020), and 258 patients (median [interquartile range] age, 67 [57-75]; 175 [67.8%] men) presented during the COVID-19 pandemic period (ie, March-April 2020). There was a significant increase in the incidence of stress cardiomyopathy during the COVID-19 period, with a total of 20 patients with stress cardiomyopathy (incidence proportion, 7.8%), compared with prepandemic timelines, which ranged from 5 to 12 patients with stress cardiomyopathy (incidence proportion range, 1.5%-1.8%). The rate ratio comparing the COVID-19 pandemic period to the combined prepandemic period was 4.58 (95% CI, 4.11-5.11; P < .001). All patients during the COVID-19 pandemic had negative reverse transcription–polymerase chain reaction test results for COVID-19. Patients with stress cardiomyopathy during the COVID-19 pandemic had a longer median (interquartile range) hospital length of stay compared with those hospitalized in the prepandemic period (COVID-19 period: 8 [6-9] days; March-April 2018: 4 [3-4] days; January-February 2019: 5 [3-6] days; March-April 2019: 4 [4-8] days; January-February: 5 [4-5] days; P = .006). There were no significant differences between the COVID-19 period and the overall pre–COVID-19 period in mortality (1 patient [5.0%] vs 1 patient [3.6%], respectively; P = .81) or 30-day rehospitalization (4 patients [22.2%] vs 6 patients [21.4%], respectively; P = .90).
Conclusions and Relevance
This study found that there was a significant increase in the incidence of stress cardiomyopathy during the COVID-19 pandemic when compared with prepandemic periods.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: June 11, 2020.
Published: July 9, 2020. doi:10.1001/jamanetworkopen.2020.14780
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Jabri A et al. JAMA Network Open.
Corresponding Author: Ankur Kalra, MD, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 224 W Exchange St, Ste 225, Akron, Ohio 44302 (email@example.com).
Author Contributions: Drs Jabri and Kalra had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Jabri and Kalra contributed equally to this work.
Concept and design: Jabri, Kalra, Alameh, Bashir, Khubber, Kanaa’N, Hedrick, Mehta, Puri, Reed.
Acquisition, analysis, or interpretation of data: Jabri, Kalra, Kumar, Alameh, Adroja, Nowacki, Shah, Kanaa’N, Hedrick, Sleik, Chung, Khot, Kapadia, Reed.
Drafting of the manuscript: Jabri, Kalra, Kumar, Alameh, Adroja, Bashir, Mehta, Reed.
Critical revision of the manuscript for important intellectual content: Jabri, Kalra, Alameh, Bashir, Nowacki, Shah, Khubber, Kanaa’N, Hedrick, Sleik, Mehta, Chung, Khot, Kapadia, Puri, Reed.
Statistical analysis: Kalra, Kumar, Alameh, Bashir, Nowacki, Reed.
Obtained funding: Kalra.
Administrative, technical, or material support: Jabri, Kalra, Adroja, Bashir, Shah, Kanaa’N, Hedrick, Khot, Reed.
Supervision: Jabri, Kalra, Mehta, Khot, Kapadia, Puri, Reed.
Conflict of Interest Disclosures: None reported.
You currently have no searches saved.
You currently have no courses saved.